Development of an Innovative, Carrier-Based Dry Powder Inhalation Formulation Containing Spray-Dried Meloxicam Potassium to Improve the In Vitro and In Silico Aerodynamic Properties

Edit Benke; Árpád Farkas; Piroska Szabó-Révész; Rita Ambrus

doi:10.3390/pharmaceutics12060535

Development of an Innovative, Carrier-Based Dry Powder Inhalation Formulation Containing Spray-Dried Meloxicam Potassium to Improve the In Vitro and In Silico Aerodynamic Properties

Pharmaceutics. 2020 Jun 10;12(6):535. doi: 10.3390/pharmaceutics12060535.

Authors

Edit Benke¹, Árpád Farkas², Piroska Szabó-Révész¹, Rita Ambrus¹

Affiliations

¹ Institute of Pharmaceutical Technology and Regulatory Affairs, Interdisciplinary Excellence Centre, University of Szeged, 6720 Szeged, Hungary.
² Centre for Energy Research, Hungarian Academy of Sciences, 1121 Budapest, Hungary.

Abstract

Most of the marketed dry powder inhalation (DPI) products are traditional, carrier-based formulations with low drug concentrations deposited in the lung. However, due to their advantageous properties, their development has become justified. In our present work, we developed an innovative, carrier-based DPI system, which is an interactive physical blend of a surface-modified carrier and a spray-dried drug with suitable shape and size for pulmonary application. Meloxicam potassium, a nonsteroidal anti-inflammatory drug (NSAID), was used as an active ingredient due to its local anti-inflammatory effect and ability to decrease the progression of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). The results of the in vitro and in silico investigations showed high lung deposition in the case of this new formulation, confirming that the interparticle interactions were changed favorably.

Keywords: aerodynamic properties; carrier-based DPI; dry powder inhaler; in silico assessment; in vitro lung model; inhalation; interparticle interactions; magnesium stearate; meloxicam potassium; pulmonary drug delivery.